Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Dermatology

Wounds

Basic fibroblast growth factor (bFGF)

In vitro studies suggest a heparin mimetic could be used to stabilize bFGF for use in indications such as wound healing. In human dermal fibroblasts, bFGF conjugated to a heparin-mimicking polymer promoted cell proliferation and showed greater stability under various stressors than unconjugated bFGF or bFGF conjugated to a different polymer. Next steps include determining long-term stability of the conjugates in different storage conditions and testing in preclinical models for wound healing.
Johnson & Johnson markets Fiblast trafermin, a human bFGF, to treat dermal ulcers.

SciBX 6(10); doi:10.1038/scibx.2013.239
Published online March 14, 2013

Patent application filed; available for licensing

Nguyen, T.H. et al. Nat. Chem.;
published online Feb. 17, 2013;
doi:10.1038/nchem.1573
Contact: Heather D. Maynard,
University of California, Los Angeles, Calif.
e-mail:
maynard@chem.ucla.edu